LRRK2-in-1 has been shown to efficiently reduce LRRK2 kinase activity [28, 31–34], and is being tested in an ongoing phase 1 clinical trial for LRRK2 mutation-carrying PD patients (clinical trial number NCT01424475; no affiliation to the authors). This evidence concerns the gene LRRK2 and Parkinson disease.